{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:09:28Z","timestamp":1788196168880,"version":"build-2803163510"},"reference-count":60,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0215","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":38,"title":["Treatment Options for Gout"],"prefix":"10.3238","author":[{"given":"Bettina","family":"Engel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Bleckwenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Weckbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"key":"10.3238\/arztebl.2017.0215_ref1","doi-asserted-by":"crossref","unstructured":"Annemans L, Spaepen E, Gaskin M, et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 2007; 67: 960\u20136","DOI":"10.1136\/ard.2007.076232"},{"key":"10.3238\/arztebl.2017.0215_ref2","doi-asserted-by":"crossref","unstructured":"Kuo C, Grainge MJ, Zhang W, Doherty M: Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649\u201362","DOI":"10.1038\/nrrheum.2015.91"},{"key":"10.3238\/arztebl.2017.0215_ref3","doi-asserted-by":"crossref","unstructured":"Cottrell E, Crabtree V, Edwards JJ, Roddy E: Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract 2013; 14: 170","DOI":"10.1186\/1471-2296-14-170"},{"key":"10.3238\/arztebl.2017.0215_ref4","unstructured":"Engel B, Bleckwenn M, Weckbecker K: [How do family practitioners treat gout? Results of a survey in NRW]. Z Allg Med 2014; 90: 277\u201381."},{"key":"10.3238\/arztebl.2017.0215_ref5","doi-asserted-by":"crossref","unstructured":"Kiltz U, Alten R, Fleck M, et al.: Langfassung zur S2e-Leitlinie Gichtarthritis (fach\u00e4rztlich). Rheumatol 2016; 75: 11","DOI":"10.1007\/s00393-016-0147-6"},{"key":"10.3238\/arztebl.2017.0215_ref6","doi-asserted-by":"crossref","unstructured":"Richette P, Doherty M, Pascual E, et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 : 29\u20134","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"10.3238\/arztebl.2017.0215_ref7","doi-asserted-by":"crossref","unstructured":"Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301\u201311","DOI":"10.1136\/ard.2006.055251"},{"key":"10.3238\/arztebl.2017.0215_ref8","doi-asserted-by":"crossref","unstructured":"Terkeltaub RA: Gout. N Engl J Med 2003; 349: 1647\u201355","DOI":"10.1056\/NEJMcp030733"},{"key":"10.3238\/arztebl.2017.0215_ref9","doi-asserted-by":"crossref","unstructured":"Campion E, Delabry L: Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82: 421\u20136","DOI":"10.1016\/0002-9343(87)90441-4"},{"key":"10.3238\/arztebl.2017.0215_ref10","doi-asserted-by":"crossref","unstructured":"Krishnan E: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49: 1229\u201338","DOI":"10.1093\/rheumatology\/keq037"},{"key":"10.3238\/arztebl.2017.0215_ref11","doi-asserted-by":"crossref","unstructured":"Taylor W, Fransen J, Jansen T, et al.: Study for updated gout classification criteria (SUGAR): identification of features to classify gout. Arthritis Care Res (Hoboken) 2015; 67: 1304\u201315","DOI":"10.1002\/acr.22585"},{"key":"10.3238\/arztebl.2017.0215_ref12","doi-asserted-by":"crossref","unstructured":"Neogi T, Jansen T, Dalbeth N, et al.: 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol 2015; 67: 2557\u201368","DOI":"10.1002\/art.39254"},{"key":"10.3238\/arztebl.2017.0215_ref13","doi-asserted-by":"crossref","unstructured":"Tausche A, Jansen TL, Schr\u00f6der HE, Bornstein SR, Aringer M, M\u00fcller-Ladner U: Gout\u2014current diagnosis and treatment. Dtsch Arztebl Int 2009; 106: 549\u201355","DOI":"10.3238\/arztebl.2009.0549"},{"key":"10.3238\/arztebl.2017.0215_ref14","doi-asserted-by":"crossref","unstructured":"Zhang W, Doherty M, Pascual E, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312\u201324","DOI":"10.1136\/ard.2006.055269"},{"key":"10.3238\/arztebl.2017.0215_ref15","doi-asserted-by":"crossref","unstructured":"Parathithasan N, Lee W, Pianta M, Oon S, Perera W: Gouty arthropathy: review of clinicopathologic and imaging features. J Med Imaging Radiat Oncol 2016; 60: 9\u201320","DOI":"10.1111\/1754-9485.12356"},{"key":"10.3238\/arztebl.2017.0215_ref16","doi-asserted-by":"crossref","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431\u201346","DOI":"10.1002\/acr.21772"},{"key":"10.3238\/arztebl.2017.0215_ref17","doi-asserted-by":"crossref","unstructured":"Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R: Lifestyle interventions for chronic gout. Cochrane Database Syst Rev 2013; 5: CD010039","DOI":"10.1002\/14651858.CD010039.pub2"},{"key":"10.3238\/arztebl.2017.0215_ref18","doi-asserted-by":"crossref","unstructured":"Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R: Lifestyle interventions for acute gout. Cochrane Database Syst Rev 2013; 11: CD010519","DOI":"10.1002\/14651858.CD010519"},{"key":"10.3238\/arztebl.2017.0215_ref19","doi-asserted-by":"crossref","unstructured":"van Durme CMPG, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landew\u00e9 RBM: Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120","DOI":"10.1002\/14651858.CD010120.pub2"},{"key":"10.3238\/arztebl.2017.0215_ref20","doi-asserted-by":"crossref","unstructured":"Janssens HJEM, Janssen M, van de Lisdonk EH, van Riel PLCM, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854\u201360","DOI":"10.1016\/S0140-6736(08)60799-0"},{"key":"10.3238\/arztebl.2017.0215_ref21","doi-asserted-by":"crossref","unstructured":"Stack A, Hanley A, Casserly L: Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. Q J Med 2013; 106: 647\u201358","DOI":"10.1093\/qjmed\/hct083"},{"key":"10.3238\/arztebl.2017.0215_ref22","doi-asserted-by":"crossref","unstructured":"Terkeltaub RA: High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62: 1060\u20138","DOI":"10.1002\/art.27327"},{"key":"10.3238\/arztebl.2017.0215_ref23","doi-asserted-by":"crossref","unstructured":"Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R: Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4: CD009920","DOI":"10.1002\/14651858.CD009920.pub2"},{"key":"10.3238\/arztebl.2017.0215_ref24","doi-asserted-by":"crossref","unstructured":"Sivera F, Wechalekar MD, Andr\u00e9s M, Buchbinder R, Carmona L: Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev 2014; 9: CD009993","DOI":"10.1002\/14651858.CD009993.pub2"},{"key":"10.3238\/arztebl.2017.0215_ref25","doi-asserted-by":"crossref","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447\u201361","DOI":"10.1002\/acr.21773"},{"key":"10.3238\/arztebl.2017.0215_ref26","doi-asserted-by":"crossref","unstructured":"Vinik O, Wechalekar M, Falzon L, Buchbinder R, van der Heijde D, Bombardier C: Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a Systematic literature review. J Rheumatol 2014; 92: 70\u20134","DOI":"10.3899\/jrheum.140465"},{"key":"10.3238\/arztebl.2017.0215_ref27","unstructured":"Engel B, Prautzsch H: [Management of gout\u2014new guidelines published by the German College of General Practitioners and Family Physicians (DEGAM)]. Z Allg Med 2014; 90: 7\u201312."},{"key":"10.3238\/arztebl.2017.0215_ref28","doi-asserted-by":"crossref","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla J: Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786\u201390","DOI":"10.1002\/art.22232"},{"key":"10.3238\/arztebl.2017.0215_ref29","doi-asserted-by":"crossref","unstructured":"Becker MA, Schumacher HR, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450\u201361","DOI":"10.1056\/NEJMoa050373"},{"key":"10.3238\/arztebl.2017.0215_ref30","unstructured":"Borstad GC, Bryant LR, Abel MP, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429\u201332"},{"key":"10.3238\/arztebl.2017.0215_ref31","doi-asserted-by":"crossref","unstructured":"Wortmann R, MacDonald P, Hunt B, Jackson R: Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010; 32: 2386\u201397","DOI":"10.1016\/j.clinthera.2011.01.008"},{"key":"10.3238\/arztebl.2017.0215_ref32","doi-asserted-by":"crossref","unstructured":"Schumacher R, Becker M, Wortmann R, et al.: Effects of Febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540\u20138","DOI":"10.1002\/art.24209"},{"key":"10.3238\/arztebl.2017.0215_ref33","doi-asserted-by":"crossref","unstructured":"Seth R, Kydd ASR, Buchbinder R, Bombardier C, Edwards CJ: Allopurinol for chronic gout. Cochrane Database Syst Rev 2014; 10: CD006077","DOI":"10.1002\/14651858.CD006077.pub3"},{"key":"10.3238\/arztebl.2017.0215_ref34","doi-asserted-by":"crossref","unstructured":"Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME: Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653","DOI":"10.1002\/14651858.CD008653.pub2"},{"key":"10.3238\/arztebl.2017.0215_ref35","doi-asserted-by":"crossref","unstructured":"Reinders M, Haagsma C, Jansen T: A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann Rheum Dis 2009; 68: 892\u20137","DOI":"10.1136\/ard.2008.091462"},{"key":"10.3238\/arztebl.2017.0215_ref36","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Kerr B, Yeh L, et al.: Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricemia. Rheumatology (Oxford) 2014; 53: 2167\u201374","DOI":"10.1093\/rheumatology\/ket487"},{"key":"10.3238\/arztebl.2017.0215_ref37","doi-asserted-by":"crossref","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, et al.: Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheumatol 2017; 69: 203\u201312","DOI":"10.1002\/art.39840"},{"key":"10.3238\/arztebl.2017.0215_ref38","doi-asserted-by":"crossref","unstructured":"Kaufmann P, T\u00f6r\u00f6k M, H\u00e4nni A, Roberts P, Gasser R, Kr\u00e4henb\u00fchl S: Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005; 41: 925\u201335","DOI":"10.1002\/hep.20634"},{"key":"10.3238\/arztebl.2017.0215_ref39","doi-asserted-by":"crossref","unstructured":"Roddy E, Zhang W, Doherty M: The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3: 443\u20139","DOI":"10.1038\/ncprheum0556"},{"key":"10.3238\/arztebl.2017.0215_ref40","doi-asserted-by":"crossref","unstructured":"Wise E, Khanna PP: The impact of gout guidelines. Curr Opin Rheumatol 2015; 27: 225\u201330","DOI":"10.1097\/BOR.0000000000000168"},{"key":"10.3238\/arztebl.2017.0215_ref41","doi-asserted-by":"crossref","unstructured":"Singh JA, Hodges JS, Asch SM: Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009; 68: 1265\u201370","DOI":"10.1136\/ard.2008.092619"},{"key":"10.3238\/arztebl.2017.0215_ref42","unstructured":"National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health: Gout. www.cdc.gov\/arthritis\/basics\/gout.htm (last accessed on 25 September 2016)."},{"key":"10.3238\/arztebl.2017.0215_ref43","doi-asserted-by":"crossref","unstructured":"Choi HK: A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010; 22: 165\u201372","DOI":"10.1097\/BOR.0b013e328335ef38"},{"key":"10.3238\/arztebl.2017.0215_ref44","doi-asserted-by":"crossref","unstructured":"Dincer HE, Dincer AP, Levinson DJ: Asymptomatic hyperuricemia: to treat or not to treat. Clev Clin J Med 2002; 69: 594","DOI":"10.3949\/ccjm.69.8.594"},{"key":"10.3238\/arztebl.2017.0215_ref45","doi-asserted-by":"crossref","unstructured":"Janssens H, Fransen J, van de Lisdonk E, van Riel P, van Weel C, Janssen M: A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010; 170: 1120\u20136.","DOI":"10.1001\/archinternmed.2010.196"},{"key":"10.3238\/arztebl.2017.0215_ref46","doi-asserted-by":"crossref","unstructured":"Jordan RW, Khan SA: The management of gout in primary care. InnovAiT 2012; 5: 503\u20138.","DOI":"10.1093\/innovait\/ins008"},{"key":"10.3238\/arztebl.2017.0215_ref47","doi-asserted-by":"crossref","unstructured":"Reuss-Borst M: [Differential diagnosis and therapy of gout]. Med Klin (Munich) 2009; 104: 710\u201320.","DOI":"10.1007\/s00063-009-1154-z"},{"key":"10.3238\/arztebl.2017.0215_ref48","doi-asserted-by":"crossref","unstructured":"Dalbeth N, Doyle AJ: Imaging of gout\u2014an overview. Best Pract Res Clin Rheumatol 2012; 26: 823\u201338","DOI":"10.1016\/j.berh.2012.09.003"},{"key":"10.3238\/arztebl.2017.0215_ref49","doi-asserted-by":"crossref","unstructured":"Rees F, Jenkins W, Doherty M: Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013; 72: 826\u201330","DOI":"10.1136\/annrheumdis-2012-201676"},{"key":"10.3238\/arztebl.2017.0215_ref50","doi-asserted-by":"crossref","unstructured":"Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primarycare population with the EULAR gout recommendations. Ann Rheum Dis 2007; 66: 1311\u20135","DOI":"10.1136\/ard.2007.070755"},{"key":"10.3238\/arztebl.2017.0215_ref51","doi-asserted-by":"crossref","unstructured":"Choi H, Atkinson K, Karlson E, Curhan G: Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165: 742\u20138","DOI":"10.1001\/archinte.165.7.742"},{"key":"10.3238\/arztebl.2017.0215_ref52","doi-asserted-by":"crossref","unstructured":"Choi H, Curhan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309\u201312","DOI":"10.1136\/bmj.39449.819271.BE"},{"key":"10.3238\/arztebl.2017.0215_ref53","doi-asserted-by":"crossref","unstructured":"Goicoechea M, de Vinuesa S, Verdalles U: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388\u201393","DOI":"10.2215\/CJN.01580210"},{"key":"10.3238\/arztebl.2017.0215_ref54","doi-asserted-by":"crossref","unstructured":"Ames B, Cathart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858\u201362","DOI":"10.1073\/pnas.78.11.6858"},{"key":"10.3238\/arztebl.2017.0215_ref55","doi-asserted-by":"crossref","unstructured":"Stamp L, Day R, Yun J: Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol 2016; 12: 235\u201342.","DOI":"10.1038\/nrrheum.2015.132"},{"key":"10.3238\/arztebl.2017.0215_ref56","doi-asserted-by":"crossref","unstructured":"Paz\u00e1r Maldonado B, So A: \u00c4tiologie und Management der Gicht. Z Rheumatol 2012; 71: 127\u201337","DOI":"10.1007\/s00393-012-0961-4"},{"key":"10.3238\/arztebl.2017.0215_ref57","doi-asserted-by":"crossref","unstructured":"Frampton J: Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs 2015; 75: 427\u201338","DOI":"10.1007\/s40265-015-0360-7"},{"key":"10.3238\/arztebl.2017.0215_ref58","unstructured":"EMA Risk Management Plan Lesinurad. www.ema.europa.eu\/ema\/index.jsp?curl=search.jsp&q=EMA%2F1488%2F2016&btnG=Search&mid= (last accessed on 25 September 2016)."},{"key":"10.3238\/arztebl.2017.0215_ref59","unstructured":"EMA public statement, 21 July 2016 EMA\/498114\/2016. www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2016\/07\/WC500210911.pdf (last accessed on 25 September 2016)."},{"key":"10.3238\/arztebl.2017.0215_ref60","doi-asserted-by":"crossref","unstructured":"Taylor T, Mecchella J, Larson R, et al.: Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125: 1126\u20131134.e7.","DOI":"10.1016\/j.amjmed.2012.05.025"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:17:37Z","timestamp":1638872257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":60,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0215","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,31]]}}}